Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis
Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja-Wyszomirska, Gideon M Hirschfield, Olivier Barbier, Piotr Milkiewicz. Hepatology: Official Journal of the American Association for the Study of Liver Diseases, 2014, February 12
Ursodeoxycholic acid (UDCA) is no longer recommended for the management of adult patients with primary sclerosing cholangitis (PSC). We undertook prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range 10-15mg/kg/day) were included. Paired blood samples for liver biochemistry, bile acids, fibroblast growth factor 19 (FGF19) were collected before UDCA withdrawal and 3 months later . . . To read further, please click on the title.
Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja-Wyszomirska, Gideon M Hirschfield, Olivier Barbier, Piotr Milkiewicz. Hepatology: Official Journal of the American Association for the Study of Liver Diseases, 2014, February 12
Ursodeoxycholic acid (UDCA) is no longer recommended for the management of adult patients with primary sclerosing cholangitis (PSC). We undertook prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range 10-15mg/kg/day) were included. Paired blood samples for liver biochemistry, bile acids, fibroblast growth factor 19 (FGF19) were collected before UDCA withdrawal and 3 months later . . . To read further, please click on the title.
RSS Feed